Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Brümmendorf
Tim H
TH
Ersöz
Inci
I
Hartmann
Ulrike
U
Bartolovic
Kerol
K
Balabanov
Stefan
S
Wahl
Alexandra
A
Paschka
Peter
P
Kreil
Sebastian
S
Lahaye
Tanja
T
Berger
Ute
U
Gschaidmeier
Harald
H
Bokemeyer
Carsten
C
Hehlmann
Rüdiger
R
Dietz
Klaus
K
Lansdorp
Peter M
PM
Kanz
Lothar
L
Hochhaus
Andreas
A
D001549:Benzamides; D015415:Biomarkers; D006098:Granulocytes / Q000648:ultrastructure*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016615:Telomere / Q000378:metabolism / Q000648:ultrastructure*; D016896:Treatment Outcome
D001549:Benzamides; D015415:Biomarkers; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate